Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Søg Study Connect


A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients - CA127-1026

Opdateret: 19 juli, 2023   |

Udskriftsvenligt sammendrag

Udskriv denne side og forsøgsvejledningen som en hjælp til at tale med din læge.
Brug vejledningen til forsøgsdeltagere for at finde rundt i processen for deltagelse i et klinisk forsøg. Forstå de vigtigste faktorer, der skal overvejes, før du beslutter dig, og find spørgsmål, du kan stille dit sundhedsteam.


  • Phase 1


  • Køn

  • 18+


  • 2


  • Recruiting


Experimental: Repotrectinib (TPX-0005)
Drug: repotrectinib (TPX-0005)

Primære egnethedskriterier

Key Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumor for which standard curative or palliative measures do not exist or are no longer effective. In case of hepatocellular carcinoma, the diagnosis should be based on at least 1 of the following: 1. The presence of at least 1 lesion, measuring ≥2 cm, with characteristic arterial enhancement and venous washout in the setting of liver cirrhosis and/or hepatitis B or C infection. 2. The presence of liver lesion(s) (as defined in inclusion criteria 3a) with alphafetoprotein ≥ 400 ng/mL. 3. Tissue confirmation. 2. For patients with genetic ROS1 or NTRK 1-3 gene fusion, tissue-based local testing should be documented. 3. Biliary obstruction for whom a biliary drain or stent has been placed are eligible. 4. Eastern Cooperative Oncology Group Performance Status scores 0 to 2. 5. The patient must have no clinically significant change in hepatic disease status within the last 30 days before screening. 6. Patient with ascites must not have a paracentesis within 3 months of screening. 7. Protocol specified baseline hematology and kidney function laboratory values Key Exclusion Criteria: 1. Concurrent participation in another therapeutic clinical study. 2. Symptomatic brain metastases or leptomeningeal involvement. 3. Major surgery within 4 weeks. 4. Clinically significant cardiovascular disease. 5. History of non-pharmacologically induced prolonged QT interval corrected for heart rate interval. 6. Known active infections requiring ongoing treatment (bacterial, fungal, or viral, including human immunodeficiency virus positivity). 7. Gastrointestinal disease or other malabsorption syndromes. 8. Current use or anticipated need for drugs that are known to be strong cytochrome P450 (CYP) 3A inhibitors or inducers.

Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information